NovoCure (NVCR) Retained Earnings (2014 - 2026)

NovoCure has disclosed Retained Earnings across 13 years of filings, most recently posting -$1.4 billion for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$1.4 billion, down 14.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 14.56% YoY), and the FY2025 annual result was -$3.4 million, up 99.7% from the prior year.
• Retained Earnings came in at -$1.4 billion for Q1 2026 at NovoCure, down from -$3.4 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$2.0 million in Q2 2023 to a low of -$1.4 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$831.5 million (2023), against an average of -$724.0 million.
• Across the five-year window, Retained Earnings plunged 35350.36% in 2022 and jumped 99.7% in 2025, its largest moves.
• NovoCure's Retained Earnings stood at -$778.5 million in 2022, then jumped by 99.3% to -$5.5 million in 2023, then slumped by 21003.13% to -$1.2 billion in 2024, then surged by 99.7% to -$3.4 million in 2025, then plunged by 39466.84% to -$1.4 billion in 2026.
• The last three Retained Earnings figures came in at -$1.4 billion (Q1 2026), -$3.4 million (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.